Escritos de Psicología / Psychological Writings
June 29, 2026
Diego Fernández Piedra, A. López, Enrique Gallego-Granero et al.
Introduction: MDMA use among young people in Spain is shaped by psychosocial factors that guide consumption patterns, motivations, and risk-reduction strategies. Objective: To investigate consumption patterns, risk perception, and consumption management (strategies and practices aimed at regulating use) in recreational contexts among young people in Spain. Method: A mixed-methods design was...
Progress in neuro-psychopharmacology & biological psychiatry
June 20, 2026
Ewen Kervadec, Pauline Mathieu, Baptiste Fauvel et al.
The renewal of psychedelic medicine has garnered significant scientific interest, with large efforts dedicated to the understanding of the complex subjective experiences induced by these substances. The Altered States of Consciousness (ASC) questionnaire represents the most comprehensive instrument for measuring such experiences yet lacks a validated French translation despite its centrality to...
PLoS One
June 18, 2026
Elisa Liberati, Hv Curran, Peter Fonagy et al.
INTRODUCTION: Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) is a potentially transformative intervention for post-traumatic stress disorder (PTSD). Despite encouraging Phase III trial results, the psychological mechanisms underpinning MDMA's therapeutic effects remain insufficiently understood. Existing research on MDMA has emphasised neurobiological processes but has...
Drug Metabolism and Personalized Therapy
June 16, 2026
Faezeh Ahmadi, Hoda Lavasani, Mohammadhosein Keshvadi et al.
OBJECTIVES: Ecstasy is commonly abused due to entactogenic effects. Although our previous studies on isolated perfused rat model confirmed inhibition of CYP2D6 by MDMA, the time for enzyme recovery was different when mirtazapine and tramadol were used as substrates. Therefore, present study intended to investigate CYP2D6 inhibition by MDMA using dextromethorphan as a well-known probe. Two...
Psychopharmacology (Berl)
June 13, 2026
Mitch Earleywine, Quinn Allen
Blinding, Expectancy, and the Active Placebo Paradox in MDMA Research.
Journal of Psychoactive Drugs
June 10, 2026
Bruno Pereira Dos Santos, Vítor Camargo Pôrto, Letícia Birk et al.
Ecstasy-type drugs are the most frequently seized synthetic drugs in Brazil, usually containing a mixture of MDMA and its analog MDA. In recent years, an increasing number of samples have been found to contain only MDA, possibly reflecting shifts in the synthetic routes of ecstasy-type substances during the COVID-19 pandemic. However, the exclusive use of MDA remains poorly characterized, and...
Tidsskr Nor Laegeforen
June 10, 2026
Tor-Morten Kvam, Ivar W Goksøyr, Lowan H. Stewart et al.
Clinical and non-clinical use of MDMA.
ChemRxiv
June 9, 2026
Matthew Gardner, Alexander Power, Anca Frinculescu et al.
High-dose MDMA tablets and variable-purity cocaine and ketamine samples are commonly encountered by drug checking services and police forces in the United Kingdom and Europe. At the time of writing, there are few simpleto-operate field-portable technologies that provide semi-quantitative information on MDMA tablet dosage or cocaine and ketamine purity at the point of sampling. We previously...
Psychoactives
June 8, 2026
Fizza Mitter, Anton Sheptooha, Janni Leung et al.
Post-traumatic stress disorder (PTSD) remains inadequately treated by existing pharmacological and psychological interventions, prompting growing interest in psychedelic-assisted psychotherapy. Although randomised controlled trials have evaluated several psychedelic agents for PTSD, to our knowledge, no prior PTSD-specific synthesis has quantitatively examined multiple agent classes within a...
University of Chicago
June 6, 2026
Ruiyan Hu
Negative Emotionality (NEM) is a trait measure that reflects a tendency toward experiencing intense negative emotions and heightened reactivity to perceived threats or stressors, contributing to challenges with social integration and interpersonal relationships. This secondary analysis in healthy volunteers (N = 30) employed a within-subject, double-blind, placebo-controlled design to...
UNC Libraries
June 5, 2026
Charlotte Rubin
Opioid use disorder (OUD) is characterized by dependence, withdrawal, and high relapse risk, yet the neuroimmune mechanisms underlying withdrawal in the amygdala remain poorly understood. This study investigated whether 3,4-methylenedioxymethamphetamine (MDMA) modulates heroin withdrawal–induced neuroinflammation in the central amygdala (CeA) and basolateral amygdala (BLA). Adult male...
Myanmar Medical Journal
June 4, 2026
Aung Kyaw Thu, Zaw Hlaing Toe, Si Thu Linn
“Happy water” has been gaining popularity among party goers. The effect of consuming this drug can be fatal. Two patients of “Happy water” overdose were admitted for reduced level of consciousness after enjoying a farewell party at nightclub. Urine for toxicology screening was found to be positive for methylenedioxymethamphetamine (MDMA), methamphetamine, diazepam and tramadol. “Happy water” is...
June 4, 2026
Jason B. Luoma, M. Kati Lear, Brian Pilecki et al.
preprint
Background: ±3,4-methylenedioxymethamphetamine (MDMA) has positive effects on socio-emotional processing and MDMA-Assisted Therapy (MDMA-AT) showed promise for treating SAD in a previous placebo-controlled trial. Aims: Develop a preliminary estimate of clinical response and safety for MDMA-AT versus waitlist in adults with SAD. Secondary aims included refinement of a standardized psychotherapy...
Translational Psychiatry
June 4, 2026
Mélusine Humbert‐droz, Anna M Becker, Jan Valenta et al.
3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is being investigated as a treatment for several psychiatric disorders, particularly posttraumatic stress disorder. Phase 2 and 3 trials typically administered a first dose of MDMA followed by a second "booster" dose 1.5-2.5 h later, to extend the acute effect duration. However, the risks and benefits of the booster dose...
European Psychiatry
June 1, 2026
Agnieszka Mechlińska, Damian Swieczkowski, Aleksander Kwaśny et al.
Introduction MDMA (3,4-methylenedioxymethamphetamine)–assisted therapy has gained growing scientific attention as a potential treatment for post-traumatic stress disorder and other mental health conditions. Although clinical studies suggest potential benefits, concerns remain regarding cardiovascular safety, methodological rigor, and variability in psychotherapeutic support (Singh et al . CNS...
June 1, 2026
Sharda More-Pol
The emergence of contemporary psychological stressors, synthetic psychoactive substance abuse, and non-substance behavioral dependency networks presents critical investigative challenges within public healthcare and classical toxicology (Agadatantra), traditionally analyzed through the concepts of Madya (intoxicants), Mada (intoxication), and severe cognitive perversion (Prajñāparādha). This...
Mental Health Weekly
June 1, 2026
Valerie A. Canady
The U.S. Department of Veterans Affairs (VA) has launched a clinical trial to evaluate the safety and efficacy of MDMA‐assisted therapy for treating severe mental health disorders, including posttraumatic stress disorder (PTSD) and alcohol use disorder, a news release announced May 26.
Drug and Alcohol Dependence Reports
June 1, 2026
Christopher Medina-Kirchner, Scott E Lukas
Ecstasy is commonly used on weekends and linked to post-use mood declines. Laboratory studies with pure MDMA rarely detect residual effects, whereas naturalistic studies more often report mood reductions. The timing and contextual drivers of these effects remain unclear. Data from seventeen participants reporting weekend ecstasy use (10 male, 7 female; 19-38 years) were drawn from a previously...
Journal of Traumatic Stress
June 1, 2026
Kadek Suhardita, Veno Dwi Krisnanda, Rikas Saputra et al.
In this commentary on Morland et al. (2026)'s recent State of the Science article on 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder (PTSD), we aim to emphasize both MDMA's therapeutic promise and its unresolved scientific challenges. Although recent trials on MDMA-assisted interventions have reported encouraging reductions in PTSD symptoms, the...